Mumbai, March 2 -- Emcure Pharmaceuticals announced the signing of a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement marks a significant step toward expanding patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India. Under the agreement, which will be effective 01 April 2026, Emcure will distribute Roche's established and globally recognised brands in the nephrology and transplant segment in India.

CellCept(R) - A globally leading immunosuppressant and original Roche innovation, supporting organ transplants worldwide since 1995.

Mircera(R) and Neorecormon(R) - Proven therapies for anemia in chronic ki...